Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid‐positive individuals
Abstract
Neurofilament light chain (NfL) is a promising blood biomarker to detect neurodegeneration in Alzheimer's disease (AD) and other brain disorders. However, there are limited reports of how longitudinal NfL relates to imaging biomarkers. We herein investigated the relationship between blood NfL and brain metabolism in AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1016/j.dadm.2019.08.002
Entities
People
- Andrea L Benedet
- Antoine Leuzy
- Aurelie Labbe
- Eduardo R. Zimmer
- Henrik Zetterberg
- Joseph Therriault
- Kaj Blennow
- Melissa Savard
- Michael Schöll
- Min S. Kang
- Mira Chamoun
- Nicholas J. Ashton
- Pedro R. Neto
- Serge Gauthier
- Sulantha Mathotaarachchi
- Tharick A Pascoal
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Eisai
- Eli Lilly and Company
- Federal University of Rio Grande do Sul
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
- GE HealthCare
- HEC Montréal
- Hoffmann-La Roche
- King's College London
- Laboratoires Servier
- Lund University
- Lundbeck
- McGill University
- McGill University Health Centre
- Meso Scale Diagnostics (United States)
- National Council for Scientific and Technological Development
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Sahlgrenska University Hospital
- Swedish Research Council
- Takeda Pharmaceutical Company
- Torsten Söderberg Foundation
- United States Department of Defense
- University College London
- University of Gothenburg